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Abstract
Catecholamines are neurotransmitters distributed throughout the body including 
adrenal glands, chromaffin tissues and other tissues innervated by post ganglionic 
adrenergic neurons. The rate of release of medullary hormones is responsible for the 
control of serum catecholamines. Thrombogenicity of catecholamines are due vari-
ous mechanisms including hypercoagulable states, endothelial damage, blood stasis 
and platelet aggregation. Oxidative stress generated by catecholamine excess causes 
coronary spasm, ultrastructural cell damage and arrhythmias. Elevated plasminogen 
activator inhibitor-1 during catecholamine excess causes hypercoagulability by hypofi-
brinosis. During stress, Catecholamines released in procoagulant environment causes 
vasoconstriction in adrenal veins resulting in venous thrombosis. Catecholamines 
generate moderately elevated levels of platelet count which enhances the risk of 
thrombosis. Hypercoagulability results in formation of coronary thrombus, rupture of 
atherosclerotic plaque and plaque progression due to gradual fibrinogen accumulation 
in the vessel walls. High levels of circulating catecholamines produce elevated levels 
thrombomodulin, the biomarkers of endothelial cell damage. In patients with hyper-
tension in catecholamine excess, resistance to blood flow and damage to the integrity 
of blood vessels lead to atherosclerosis. A case report has been discussed which sug-
gests an association of thrombotic tendency and catecholamine excess.
Keywords: catecholamines, thrombotic tendencies, atherosclerosis, 
hypercoagulation, platelet aggregation, endothelial damage, blood stasis
1. Introduction
Catecholamines are the class of neurotransmitters and hormones produced 
by the adrenergic nervous system, with a core structure of catechol and an amine 
group, regulating physiological processes [1]. Catechol refers to ortho-dihydroxy-
benzene and epinephrine and norepinephrine are the two major ethanolamine 
derivatives [2] occurring in the blood [3]. About 80% of epinephrine and 20% of 
norepinephrine are produced and released by the human adrenal medulla with a 
small amount of dopamine along with it [2].
1.1 Catecholamine biosynthesis
Catecholamines are synthesised and secreted from the chromaffin cells in 
adrenal medulla and sympathetic paraganglia [4]. Chromaffin granules produce 
catecholamines and fairly high concentration of adenosine triphosphate (ATP) and 
adenosine diphosphate (ADP) for active transport mechanism [2].
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Syntheses of catecholamines occur at two levels [5]:
1. Sympathetic nervous fibre extremities for norepinephrine.
2. Chromaffin cells of adrenal medulla for both epinephrine and norepinephrine.
Tyrosine hydroxylase is the rate limiting enzyme of catecholamine synthesis. 
Tyrosine from dietary proteins is transported to the brain and tyrosine hydroxylase 
(in the dopaminergic and noradrenergic neurons of CNS and in the non-neuronal 
cells of gastrointestinal tract and kidneys) converts it to 3,4-dihydroxyphenylala-
nine (DOPA). In the presence of aromatic L-amino acid decarboxylase, DOPA is 
converted to dopamine (DA) which is transported to vesicular storage granules. It 
may be released in the dopaminergic neurons or converted to norepinephrine in the 
noradrenergic neurons by dopamine beta-hydroxylase [6]. Norepinephrine is con-
verted to epinephrine by phenyl ethanolamine-N-methyltransferase (PNMT) [4].
Medullary hormones synthesised and stored in the chromaffin granules are a 
pool of ready to release hormones upon stimulation [7].
1.2 Catecholamine functions and receptors
Norepinephrine and epinephrine together contribute to an increase in cardiac 
output, heart-rate, respiration, blood pressure, blood flow to muscles, alertness 
and decrease in splanchnic and renal blood flow [2]. Norepinephrine alone causes a 
decrease in heart-rate indirectly as a result of reflex bradycardia because of vaso-
constriction effects [2].
Functions of catecholamines are mediated and regulated by alpha, beta adreno-
receptors and dopamine receptors. Each receptor located at distinct locations serves 
different functions and actions.
Alpha-1 receptors mediate adrenergic vasoconstriction [8]. Alpha-2 receptor 
stimulation causes inhibition of norepinephrine secretion [6]. Three subtypes of 
α2 receptors are α2A, α2B, and α2C. Alpha-2A in the peripheral postsynaptic region 
contributes to vasoconstriction in different vascular beds [8]. Beta-1 receptor 
stimulation causes positive inotropic and chronotropic action [6]. Beta-2 receptors 
stimulate vasodilation [9]. Beta 3 causes lipolysis in fatty cells and increase renin 
secretion [9].
Two types of dopamine receptors are D1 and D2.Stimulation of D1 receptors in 
coronary, renal, mesenteric and cerebrovascular beds causes vasodilation, diuresis 
and natriuresis. D2 receptor stimulation in presynaptic nerve endings causes inhibi-
tion of norepinephrine release [6].
1.3 Catecholamine metabolism
Neuronal catecholamines get metabolised intraneuronally after leakage from 
its stores [1]. Catecholamine metabolism mainly occurs in the liver [2]. There 
are two major catecholamine metabolites (i) metanephrines (constitutes 15% of 
urinary catecholamine) and (ii) vanillylmandelic acid, VMA (major end-point of 
norepinephrine and epinephrine metabolism [1] and constitutes 85% of excreted 
catecholamine) [2].
1.4 Catecholamine inactivation
Two major enzymes involved in the inactivation of catecholamines are catechol-
o-methyl transferase (COMT) and monoamine oxidase (MAO).COMT adds methyl 
3Thrombotic Tendencies in Excess Catecholamine States
DOI: http://dx.doi.org/10.5772/intechopen.81929
group to hydroxyl at 3-position of catechol ring and MAO catalyses oxidative 
deamination reaction [2].
Norepinephrine is inactivated by two processes (i) reuptake into the nerve 
terminals by the active carrier mechanism associated with Na+-K+-ATPase of which 
some part is stored to granular vesicles and the rest is metabolised and (ii) extra-
neuronal accumulation to vascular smooth muscles [10].
1.5 Catecholamine excess
The three distinct peripheral catecholamine systems are [11].
1. Sympathetic nervous system (SNS)
2. Adrenomedullary hormone system (AHS)
3. Dopamine autocrine/paracrine system (DOPA)
Sympathetic nervous system: the measure of norepinephrine release in the spe-
cific regions allows the clinical assessment of organ-specific sympathetic nervous 
tone and penetrating analysis of SNS in the pathophysiology of a disease state [12].
Adrenomedullary hormone system: the catecholamines stored in the chromaffin 
cells get released by innervations of preganglionic sympathetic fibres of splanchnic 
nerves and get dispersed after its entry to medulla [2].
Dopamine derived from plasma DOPA acts as an autocrine/paracrine substance. 
Human urine contains higher concentration of dopamine and its metabolites rather 
than norepinephrine and its metabolites as dopamine is generated in the non-
noradrenergic and non-adrenergic cells [13].
Catecholamines are distributed throughout the body including adrenal glands, 
chromaffin tissues and other tissues innervated by post ganglionic adrenergic neu-
rons [3]. The rate of release of medullary hormones is responsible for the control of 
serum catecholamines [2].
The cellular uptake and metabolism of catecholamines in the extraneuronal 
tissues and the exogenous administration of catecholamines together contribute 
to 25% of total metabolism of catecholamines produced in the SNS and adrenergic 
chromaffin cells [1].
During stressful conditions, the level of enzymes catalysing biosynthesis of 
catecholamines increase and enzymes degrading the catecholamines decrease [14]. 
Stress-induced changes in the adrenergic receptors occur due to the combination of 
neuronal and extraneuronal catecholamine uptake system, level of cAMP, density 
of adrenoceptor subtypes and coupling of agonist receptor complex with different 
G-proteins [14].
During chronic stress, increased levels of catecholamines produce aminolutins 
and oxyradicals. Oxidative stress thus generated causes coronary spasm, ultrastruc-
tural cell damage and arrhythmias [14]. They also cause Ca2+overload and cardiac 
dysfunction by acting on beta-1-adrenoceptor signal transduction pathway [14].
1.6 Catecholamine excess in pheochromocytoma
Catecholamine excess is seen in certain types of tumour such as pheochromo-
cytomas that are functional tumours of the chromaffin cells [15]. Norepinephrine 
secreting tumours are known to cause hypertension (in 80–90% of these patients 
[4]) and hypertensive crisis and their abrupt release may cause arrhythmias 
[6]. Of this nearly 40% of the patients suffer from sustained hypertension 
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(norepinephrine secreting tumours), 45% from paroxysmal hypertension (epi-
nephrine secreting tumours) and 5–15% from normotension (dopamine secreting 
tumours) [4].
Other vasoactive substances like neuropeptide Y, adrenomedullin and atrial 
natriuretic peptide contribute to hypertension in these patients [6]. Neuropeptide 
Y increase coronary and peripheral vascular resistance and potentiate norepineph-
rine-induced vasoconstriction [7].
Pheochromocytoma produces enormous amounts of catecholamines due to 
mutation of succinate dehydrogenase by oxidative phosphorylation deficit [6].Two 
major mechanisms in pheochromocytoma that leads to catecholamine excess are 
translocation of dopamine into storage granules and the presence of dopamine beta 
hydroxylase enzyme [1].
In extra-adrenal tumours, norepinephrine levels are high, in adrenal tumours 
both norepinephrine and epinephrine are in excess and in multiple endocrine 
neoplasia type 2 and neurofibromatosis type 1, epinephrine levels are high [6].
In non-functional/silent pheochromocytoma, metanephrine levels are elevated 
instead of catecholamines [6].
Complication of pheochromocytoma in hypertensive crisis are sustained 
hypertension by continuous elevated levels of catecholamine causing vasoconstric-
tion and orthostatic hypertension due to reduced blood volume that resulting in 
vasoconstriction, postural tachycardia and postural hypotension [4].
Neurological complications are hypertensive encephalopathy, haemorrhage (due 
to paroxysmal hypertension) and acute ischemic stroke (due to postural hyperten-
sion) [4].
In 78% of pheochromocytoma patients, thrombus exists at the time of their 
tumour discovery and 75% of the secondary thrombi are located in inferior vena 
cava or heart or both [16]. Venous thromboembolism and acute arterial thrombi 
are well described in such patients [17] but evidence of stroke, aortic thrombi and 
myocardial infarction are fewer [18].
Several mechanisms explain thrombotic tendencies in pheochromocytomas by 
elevated catecholamines:
• Catecholamines generate moderately elevated levels of platelet count which 
enhance the risk of thrombosis [19].
• Platelet aggregation is increased in pheochromocytoma [18] and produce 
thrombi in low-flow areas causing coronary events [19].
• Contributing factors to thrombus formation are erythropoietin, pro-coagula-
tion and serotonin [6].
• Catecholamine excess in other tumours like paragangliomas may cause ADP-
mediated platelet aggregation leading to thrombotic events [20].
• During stress, catecholamine release in procoagulant environment causes 
vasoconstriction in adrenal veins resulting in venous thrombosis [21].
• Loss of antithrombin III in glomerular diseases associated with hypertension 
may increase thrombotic risk [22].
• Pheochromocytoma causes thrombosis of caudal vena cava and aortic throm-
boembolism through Virchow’s triad list [20, 22]:





Mortality of pheochromocytoma patients occur due to either acute intramyocar-
dial necrosis or diffuse patchy myocardial fibrosis [23].
2.  Mechanisms associated with thrombus formation in catecholamine 
excess
Thrombus formation and dissolution are physiological processes with dynamic 
balance between procoagulation and anticoagulation mechanism [24]. Catecholamine 
excess contributes to long-term development of atherosclerosis and cardiovascular 
risk [25] due to their effect on carbohydrate and lipid metabolism [23].
3. Cascade of thrombus formation
Thrombotic process occurs by the activation of coagulation cascade in different 
phases [26].
1. Initiation phase—the extrinsic pathway of coagulation in which low amounts 
of active pro-coagulant factors are produced.
2. Amplification phase—level of coagulation factors increase.
3. Propagation phase—active coagulation factors are generated like thrombin 
which binds to phospholipid at the surface of activated platelets.
4. Stabilization phase—thrombin provides strength and stability to growing clot 
and thrombin activatable fibrinolysis inhibitor.
Injury to the vessel walls due to resistance, in catecholamine excess states, 
causes exposure of glycoprotein tissue factor (TF) to the blood. After exposure, 
TF bind to Factor VII/VIIa and forms tertiary complex in the presence of calcium 
to activate factor X to Xa, factor IX to IXa and factor VIIa. At the site of injury, 
platelet activation, conversion of fibrinogen to fibrin and thrombus formation 
occurs. Platelets are able to regulate their gene and protein expression for binding 
to sub endothelium [26].
Diseases affecting Virchow’s triad can induce clot formation [27].
4. Hypercoagulability
Hypercoagulability is the tendency to produce thrombosis by inherited or 
acquired molecular defects. Thrombus is formed based on the number of predispos-
ing factors and environmental stress [13].
Cancer is the second major cause of hypercoagulation with clinical thrombosis 
in 15% and thrombosis on autopsy in 50% patients [28].
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Catecholamines increase plasminogen activator inhibitor-1 (PAI-1) mRNA by 
expression of PAI-1 genes in the cardiovascular system by neurological and neuro-
endocrine mechanisms via beta-adrenoreceptors [29]. PAI-1, a member of serine-
protease inhibitor, inhibits both tissue type and urinary-type plasminogen activator. 
Elevated PAI-1 during catecholamine excess causes hypercoagulability by hypofi-
brinosis. High levels of PAI-1 act on adipokines in the atherogenic process and cause 
atherosclerotic lesions and atheromas [30]. Epinephrine regulates Beta-mediated 
tissue-type plasminogen activator to produce an increase in fibrinolytic capacity [25].
Antithrombin III (AT-III) inhibits the protein-splitting reaction, characteristic 
of haemostasis, by interfering with the activity of four of the serine proteases 
and antagonising thrombin [31]. Hypertension associated glomerular diseases 
in catecholamine excess may cause loss of AT-III by protein loss in the urine. 
Hypoalbuminemia and hypercholesterolemia in Proteinuria causes platelet hyper-
aggregability and aggravate hypercoagulability. Increased levels of fibrinogen and 
thromboxane in protein-losing nephropathy contribute to thrombosis [27].
Hypercoagulability result in formation of coronary thrombus, rupture of ath-
erosclerotic plaque and plaque progression due to gradual fibrinogen accumulation 
in the vessel walls [24].
In patients with borderline hypertension, coagulation activation occurs before 
clinical manifestations of vascular damage appear [32].
5. Platelet aggregation
In thrombus formation, a high proportion of platelets translocates from their 
initial point of attachment to the injured vessel wall and forms a firm adhesion 
contact [31]. Catecholamine infusion induces platelet aggregation in ex-vivo 
and animal models [16]. They activate platelets by interacting with platelet 
α2-adrenoreceptor in in-vitro studies. Stimulation of α1-adrenoreceptor inhibits 
platelet aggregation by inactivating platelet response to epinephrine [25]. In-vivo 
adrenergic infusion causes platelet activation and an increase in platelet size, 
aggregation and releasing factors [24]. Elevated factor V: C, factor VIII: C, v 
Willebrand Factor: Ag, tissue-plasminogen activator (t-PA): Ag, contribute to risk 
of atherothrombotic events [25]. Redistribution of cardiac blood flow in catechol-
amine infusion causes regional slowing of blood flow and enhanced tendency for 
intravascular platelet aggregation [23].
The anticoagulative effect of epinephrine is explained by a 50% decrease in 
the ratio of maximal coagulation activation and maximal fibrinolytic activa-
tion by decreased tumour necrosis factor (TNF) and interleukin (IL) 10 [33]. 
Epinephrine induce fibrinogen receptor exposure and fibrinogen binding to 
potentiate platelet aggregation. Epinephrine infusion causes short-term recruit-
ment of platelets and functionally active Factor VIII from the spleen for thrombus 
formation. They discharge high molecular von Willebrand Factor (vWF) which 
increase the activity of platelet adhesion from its storage compartments. Elevated 
epinephrine levels increase platelet deposition on the atherosclerotic vessels with 
high local shear rate [25].
Norepinephrine activates platelet aggregation in-vivo by stimulating 
α2-adrenoreceptor [24].
It causes platelet aggregation in two phases [16]:
• Initial reversible aggregation.
• Simulated release of adenosine diphosphate.
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Norepinephrine initiates platelet thrombosis by directly damaging the endothe-
lial walls of vessels and breaking its integrity [24]. In acute mental stress, 60% of 
variation in thrombin formation depends on amount of norepinephrine secreted 
and sensitivity of β2-adrenergic receptor [19].
6. Clotting time
Adrenergic activation by epinephrine injection increases factor VIII: C and cause 
a decrease in clotting time. In-vivo adrenergic infusion stimulate β-2 adrenergic 
vascular receptors to release clotting factors like FVIII, v WF, and t-PA from endo-
thelium to the circulation [24] resulting in thrombotic risk in both coronary artery 
disease and hypertension [25].
7. Endothelial damage
Endothelium maintains balance between prothrombotic and atherothrombotic 
tendencies [27]. Endothelial cells provide a non-thrombogenic surface that inhibits 
platelets and blood cells from adhering and activating coagulation cascade [34]. 
Antithrombotics like thrombomodulin, heparin sulfate, tissue factor pathway 
inhibitor and protein S are involved in reducing the activation of AT III and protein 
c to elevate antithrombotic tendencies. Synthesis and induction of prothrombotic 
mediators such as tissue factor and antifibrinolytic factors like PAI-1 take part in 
prothrombotic tendencies [27].
Disproportion in the tendencies causes endothelial damage where suben-
dothelial proteins are exposed and favour platelet adhesion [27]. According 
to Gando et al. [35], endothelial damage can occur due to both exogenous and 
endogenous release of catecholamines. High levels of circulating catecholamines 
produce elevated levels thrombomodulin, the biomarkers of endothelial cell 
damage [36]. Due to loss of endothelial cell protection and expression of pro-
coagulant and prothrombotic molecules, platelets adhere to the subendothelial 
surface and release ADP and thromboxane A2 causing imbalance in haemostasis 
and thrombosis [37].
8. Blood stasis
Blood stasis plays an important role in the formation of thrombus. Thrombus 
forms in regions of blood stasis like narrow artery due to atheromatous plaque, 
mechanical vasoconstriction, prolonged immobilisation and varicose vein. From 
the injured tissue, tissue thromboplastin produced causes initial thrombus forma-
tion followed by platelet activation by thrombin. Thrombin transforms fibrinogen 
to insoluble fibrin and release to stagnant blood [36].
In patients with hypertension in catecholamine excess, resistance to blood flow 
and damage to the integrity of blood vessels lead to atherosclerosis [27, 32]. Three 
mechanisms explain the overall increased vascular resistance [37]:
(i) Rarefaction of arterioles and capillaries.
(ii) Reduced internal diameter of arterioles.
(iii) Increase in arterial and arteriolar wall mass.
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The significant role of sympathetic nervous system in elevated haemostatic activ-
ity in atherosclerosis and thrombus formation explains the role of catecholamines in 
cardiovascular diseases and associated arterial thrombus formation [25]. The factors 
associated with thrombosis in different mechanisms are summarised in Table 1.
9. Management of thrombosis
Hypertension associated with catecholamine excess plays an important role in 
the thrombus formation by mechanisms explained above. So treatment for hyper-
tension is the primary objective in treatment and prevention of thrombotic tenden-
cies. The most preferred antihypertensive is phenoxybenzamine which is an alpha 
and beta receptor antagonist given at 10 mg once a day with gradual dose titration 
to 30 mg three times a day. Appropriate anti-coagulation with heparin is vital for 
patients with risk of thrombosis to prevent devastating outcomes [19].
Removal of tumours producing excess catecholamines play a crucial role in alle-
viating symptoms associated with hypertension and thus thrombus formation. Due 
exaggerated fall in blood pressure after surgical removal of these tumours, adequate 
vascular volume replacement with oral fluids and salt is recommended [38].
Here in a case report has been discussed which suggests an association of throm-
botic tendency and catecholamine excess.
10. Case report
A Case report on cerebral venous thrombosis due to pheochromocytoma in a 
patient with Von Hippel Lindau (VHL) mutation [39] explains an unusual connec-
tion between thrombosis and pheochromocytoma in a 15 year old boy with pheo-
chromocytoma and associated hypertension. The patient was primarily presented 
with cerebral venous thrombosis and seizures. Initial examination revealed left 
S. No. Mechanism of thrombosis Factors involved in thrombosis




2. Platelet aggregation 1. Factor V: C
2. Factor VIII: C
3. v Willebrand factor (v WF)
4. t-PAI-1
5. Tumour necrosis factor (TNF)
6. Interleukin 10 (IL-10)
3. Clotting time 1. Factor VIII:C
2. (v WF)
3. t-PAI-1
4. Endothelial damage 1. t-PAI-1
2. Thrombomodulin
3. Thromboxane A2
5. Blood stasis 1. Thromboplastin
2. Thrombin
Table 1. 
Summary of factors associated with thrombosis.
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frontoparietal hematoma and superior sagittal and transverse sinus thrombus for 
which he was treated with heparin and antiepileptics. Follow-up showed elevated 
blood pressure and high urine catecholamine levels. The diagnosis of abdominal 
mass after evaluation for consistent elevated blood pressure turned out to be pheo-
chromocytoma. He underwent para-aortic dissection and right adrenalectomy.
VHL disease is an autosomal, dominant inherited tumour syndrome which 
occurs as a result of a germline mutation in the VHL gene. Even though its associa-
tion with pheochromocytoma is under-studied, VHL proteins are found to cause 
tumorigenesis in pheochromocytoma by induction of either gain of function, 
dominant negative effect or gene dosage effect in chromaffin cells [40].
Some mechanisms are established to explain the association of Catecholamine 
excess in pheochromocytoma and thrombus formation:
1. Tumours produce different chemicals with prothrombotic nature that cause 
hypercoagulability as a paraneoplastic feature [41]. The release of proco-
agulants, fibrinolytics and proteolytic factors induce thrombosis. Neoplastic 
vascular invasion damages the thromboresistant properties of vessel wall and 
tumour cell attachment to the endothelial surface leading to endothelial retrac-
tion and exposure of basement membrane. The damaged endothelial cells and 
matrix cause platelet adhesion and aggregation by release of procoagulatory 
and antagonistic substances [42].
2. Adrenal tumours release excess catecholamines and cause thrombophilia and 
clot formation [16].
3. In the case of VHL mutation, certain changes are produced in the Hypoxia 
inducible factor (HIF) resulting in polycythaemia and increased venous 
thrombosis [43]. HIF regulates both oxygen hemostasis and erythropoietin 
receptor expression [44, 45].
To associate hereditary disorders with thrombosis in excess catecholamine state 
is restricted because of unavailability of literatures explaining the same. Excess 
catecholamines themselves produce thrombosis even though an inherent mutation 
of VHL was found in the above patient as a cause of thrombosis. Hypertension 
associated with high catecholamine levels make a patient more prone to thrombosis 
than others with normal blood pressure. In patients with tumours such as pheochro-
mocytoma and paraganglioma, there is high catecholamine levels which increase 
the risk of thrombotic tendencies compared to other patients with catecholamine 
excess alone.
11. Conclusion
Though there have been evidences of thrombus formation after infusion of 
catecholamines in animals and humans, available evidence of the exact mechanism 
of thrombotic tendencies is scanty. Catecholamine excess states are a diagnostic 
challenge due to heterogenous clinical presentation like fluctuating hyperten-
sion in young which may not attract enough clinical and laboratory attention. 
Thrombogenicity of catecholamines are due various mechanisms including 
hypercoagulable states, endothelial damage, blood stasis and platelet aggregation. 
Surgical removal of tumours associated with catecholamine excess provide a clinical 
approach in treating abnormalities of thrombus formation.
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PNMT phenyl ethanolamine-N-methyl transferase
COMT catechol-O-methyl transferase
MAO monoamine oxidase
SNS sympathetic nervous system
ANS autonomic nervous system
DOPA dopamine autocrine/paracrine system
PAI-1 plasminogen activator inhibitor-1
AT-III antithrombin III
t-PA tissue plasminogen activator
TNF tumour necrosis factor
IL interleukin
v WF von Willebrand factor
VHL Von Hippel Lindau
HIF hypoxia inducible factor
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